Infantile Myofibromatosis With Cutaneous, Visceral, and CNS Involvement: A Multimodal Approach to Therapy

J Pediatr Hematol Oncol. 2023 Oct 1;45(7):e921-e923. doi: 10.1097/MPH.0000000000002717. Epub 2023 Jul 13.

Abstract

Background: Infantile myofibromatosis (IM) is a rare benign tumor of infancy. Cases with solitary and multicentric disease usually spontaneously regress, but multicentric disease with visceral involvement carries a poor prognosis. Few cases of multicentric disease with central nervous system (CNS) involvement have been reported, and none report survival.

Observations: We present a newborn with multicentric IM with cutaneous, visceral, and CNS involvement. She was treated with vinblastine, methotrexate, and the novel addition of intrathecal methotrexate with treatment response after 1 year of therapy.

Conclusions: Multicentric IM with CNS involvement can be successfully treated with a multimodal approach of chemotherapy with the addition of intrathecal methotrexate and surgery.

MeSH terms

  • Female
  • Humans
  • Infant, Newborn
  • Methotrexate* / therapeutic use
  • Myofibromatosis* / pathology
  • Myofibromatosis* / therapy
  • Vinblastine / therapeutic use

Substances

  • Methotrexate
  • Vinblastine

Supplementary concepts

  • Fibromatosis, Congenital Generalized